Today: 30 June 2026
CBA share price: Commonwealth Bank stock steadies after ASX selloff as earnings loom
8 February 2026
2 mins read

CBA share price: Commonwealth Bank stock steadies after ASX selloff as earnings loom

Sydney, Feb 8, 2026, 10:19 AEDT — The session has ended.

  • Commonwealth Bank of Australia shares finished 0.2% lower at A$158.91, faring better than the wider market’s decline.
  • With half-year numbers due Feb. 11, investors are bracing for any clues on margins, cost pressures, or bad debt trends from the bank.
  • Investors are keeping an eye on the Reserve Bank’s cash-rate hike, along with mortgage repricing set for later in February.

Commonwealth Bank of Australia slipped 0.23% to close at A$158.91 on Friday, a softer decline compared to the S&P/ASX 200’s steeper 2.03% drop as investors pulled back before the weekend.

Australian markets remain closed through Monday, so traders are already eyeing what CBA has lined up for a packed week ahead. The bank drops its half-year numbers on Feb. 11, and has scheduled a briefing the same day featuring Chief Executive Matt Comyn and CFO Alan Docherty.

The bank’s figures tend to influence how the entire sector is viewed during earnings season, especially when it comes to net interest margin—the gap between income from loans and outlays on deposits and funding. Another key point: these results give early hints about shifts in credit costs.

The macro picture’s changed as well. On Feb. 3, the Reserve Bank of Australia bumped its cash rate target up to 3.85%, reigniting questions about where funding costs might head for both lenders and borrowers.

Australia’s big four banks aren’t wasting time passing through the increase. According to Reuters, CBA and the other majors bumped up variable home-loan rates by 25 basis points. Customers will see the higher rates kick in sometime between Feb. 13 and Feb. 17—exact dates vary by lender.

Friday saw the rest of the big banks slide further than CBA. Westpac dropped 1.20%, ANZ shed 1.52%, and NAB slipped close to 1.6%, pricing data showed.

CBA pointed to a few moving pieces in its latest results. According to an ASX filing, the bank set aside a A$68 million pre-tax provision for an extra goodwill payment to certain customers after ASIC’s Better Banking review. Beyond that, it logged A$53 million in other operating income from non-recurring items—a milestone payout from the sale of Commonwealth Insurance Limited, plus a fair-value gain from its Gemini investment following the IPO.

Those one-off items aren’t enough to move the stock by themselves. Still, they tend to cloud the numbers, making that “cash” profit figure—Australia’s own adjusted metric—trickier to line up with last year’s.

Dividends are set to take the spotlight. CBA notes it tends to reveal dividends alongside its half-year results in February, and those interim payouts generally land in March.

Another wildcard: rate forecasts. Cherelle Murphy, chief economist at EY Oceania, called the February increase “unusual” in its timing, telling the Associated Press it leaves the door ajar for additional tightening if growth heats up. AP News

Still, things can easily turn against the bulls. Higher rates could hit harder, pushing up arrears and slowing loan growth. Margins might get squeezed too, with deposit competition intensifying right as investors demand tighter cost control.

Sydney trading picks up again Monday, and traders look set to tread lightly with CBA’s Feb. 11 result and investor briefing on the radar. The first round of revised mortgage rates lands later in the month.

Khadija Saeed is a financial markets reporter at TS2.tech, specializing in stocks, technology and emerging industries. She studied economics and finance at the London School of Economics and previously worked in market research before moving into financial journalism. Her coverage focuses on the companies, innovations and economic trends influencing global investors.

Stock Market Today

  • CELZ Jumps 252% as Creative Medical Technology Drops Equity Offer
    June 30, 2026, 12:50 PM EDT. Shares of Creative Medical Technology Holdings (NASDAQ:CELZ) shot up 252% Tuesday after the company pulled its June 25 S-1 for an equity and warrant deal. CELZ said it had not issued any shares under the canceled filing. Trading was heavy, hitting 146.1 million shares-almost 40 times its 3.7 million shares outstanding. The shelved offer would have meant 3.05 million new shares and warrants for another 6.09 million. CEO Timothy Warbington said they decided not to go ahead with the fundraising plan. Biotech ETFs didn't move much, pointing to a CELZ-specific jump. Still, analysts say cash remains tight, with limited room for rounds of regulatory approvals after December 2027.
Confluent stock edges higher as IBM deal vote nears after fresh merger filing
Previous Story

Confluent stock edges higher as IBM deal vote nears after fresh merger filing

US Economic Calendar Today: Stock Futures Hold Steady as Traders Eye Fed Speeches, Treasury Buyback and Delayed Jobs Data
Next Story

US Economic Calendar Today: Stock Futures Hold Steady as Traders Eye Fed Speeches, Treasury Buyback and Delayed Jobs Data

Go toTop